Fresenius Medical Care (NYSE:FMS) Now Covered by StockNews.com

StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS) in a research report sent to investors on Saturday. The firm issued a strong-buy rating on the stock.

A number of other equities research analysts have also issued reports on FMS. Truist Financial increased their target price on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a report on Monday, October 7th. Berenberg Bank began coverage on Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price objective on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Fresenius Medical Care presently has an average rating of “Moderate Buy” and a consensus target price of $24.30.

Fresenius Medical Care Stock Down 0.8 %

Shares of FMS opened at $21.22 on Friday. The company’s 50-day simple moving average is $20.50 and its 200-day simple moving average is $20.22. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.09 and a current ratio of 1.37. Fresenius Medical Care has a 1 year low of $17.49 and a 1 year high of $22.76. The stock has a market capitalization of $12.45 billion, a PE ratio of 17.68, a P/E/G ratio of 0.98 and a beta of 0.91.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its position in shares of Fresenius Medical Care by 11.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 22,161 shares of the company’s stock worth $472,000 after purchasing an additional 2,233 shares during the last quarter. Moran Wealth Management LLC increased its stake in Fresenius Medical Care by 47.0% in the third quarter. Moran Wealth Management LLC now owns 233,376 shares of the company’s stock valued at $4,971,000 after purchasing an additional 74,621 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Fresenius Medical Care during the third quarter worth approximately $420,000. Venturi Wealth Management LLC lifted its position in shares of Fresenius Medical Care by 1,045.8% during the 3rd quarter. Venturi Wealth Management LLC now owns 5,259 shares of the company’s stock worth $112,000 after buying an additional 4,800 shares during the last quarter. Finally, Crossmark Global Holdings Inc. boosted its holdings in shares of Fresenius Medical Care by 60.4% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 62,889 shares of the company’s stock valued at $1,340,000 after buying an additional 23,692 shares in the last quarter. Institutional investors and hedge funds own 8.25% of the company’s stock.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.